VYGR - Voyager Therapeutics, Inc.
IEX Last Trade
5.69
0.010 0.176%
Share volume: 6,929
Last Updated: Fri 27 Dec 2024 08:30:02 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$5.68
0.01
0.18%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-08 | 2023-03-07 | 2023-05-09 | 2023-08-03 | 2023-11-06 | 2024-02-28 | 2024-05-13 | |
| Assets | |||||||||
| Total Assets | 188.605 M | 182.480 M | 159.356 M | 336.294 M | 315.536 M | 294.653 M | 351.281 M | 469.592 M | |
| Current Assets | 151.628 M | 146.942 M | 124.499 M | 302.625 M | 282.176 M | 261.925 M | 319.684 M | 409.137 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 3.421 M | 5.079 M | 5.012 M | 3.983 M | 6.080 M | 5.736 M | 4.354 M | 6.112 M | |
| Short Term Investments | 3.421 M | 5.079 M | 5.012 M | 3.983 M | 6.080 M | 5.736 M | 4.354 M | 6.112 M | |
| Total Receivables | 151.000 K | 10.225 M | 639.000 K | 25.328 M | 3.350 M | 3.253 M | 84.455 M | 3.457 M | |
| Current Cash | 148.056 M | 131.638 M | 118.848 M | 273.314 M | 272.746 M | 252.936 M | 230.875 M | 399.568 M | |
| Total Non-current Assets | 36.977 M | 35.538 M | 34.857 M | 33.669 M | 33.360 M | 32.728 M | 31.597 M | 60.455 M | |
| Property Plant Equipment | 19.071 M | 18.082 M | 17.857 M | 17.138 M | 17.239 M | 17.109 M | 16.494 M | 17.381 M | |
| Other Assets | 1.515 M | 1.515 M | 17.000 M | 1.515 M | 1.593 M | 1.593 M | 1.593 M | 2.890 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 188.605 M | 182.480 M | 159.356 M | 336.294 M | 315.536 M | 294.653 M | 351.281 M | 469.592 M | |
| Total liabilities | 128.553 M | 102.657 M | 100.336 M | 119.333 M | 116.510 M | 118.433 M | 114.961 M | 128.706 M | |
| Total current liabilities | 97.932 M | 73.242 M | 72.591 M | 19.939 M | 45.398 M | 61.688 M | 64.508 M | 72.553 M | |
| Accounts Payable | 1.218 M | 1.337 M | 2.566 M | 3.698 M | 1.659 M | 3.270 M | 1.604 M | 7.579 M | |
| Other liabilities | 8.880 M | 8.391 M | 7.451 M | 79.873 M | 52.383 M | 38.826 M | 50.453 M | 14.158 M | |
| Current long term debt | 0.000 | 0.000 | 2.832 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 20.294 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 8.880 M | 8.391 M | 7.451 M | 79.873 M | 52.383 M | 38.826 M | 50.453 M | 14.158 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 60.052 M | 79.823 M | 59.020 M | 216.961 M | 199.026 M | 176.220 M | 236.320 M | 340.886 M | |
| Common stock | 38.298 M | 38.508 M | 38.572 M | 40.632 M | 43.520 M | 43.865 M | 44.066 M | 57.117 M | |
| Retained earnings | -387.510 M | -369.886 M | -393.512 M | -269.468 M | -291.676 M | -317.577 M | -261.182 M | -272.512 M |